Moneycontrol PRO
Open App

business

3-Point Analysis | Gland Pharma: What should investors do with stock now?

Gland Pharma's IPO subscription response was tepid compared to the recent entrants. However, it closed 21 percent higher than the issue price of Rs 1500. Let's find out what should investors do post the listing

LATEST VIDEOS

Watch More →

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Sections
ISO 27001 - BSI Assurance Mark